Valuation: InDex Pharmaceuticals Holding AB (publ)

Market Cap 1.73B 180M 157M 145M 134M 253M 17.33B 257M 680M 8.47B 676M 661M 29.19B P/E 2024
-14.5x
P/E 2025 -3.86x
Enterprise Value 1.2B 124M 109M 100M 92.08M 174M 11.95B 177M 469M 5.84B 466M 456M 20.13B EV / Sales 2024
1,077x
EV / Sales 2025 945x
Free-Float
21.73%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 48 2022-12-31
Director of Finance/CFO 54 2023-12-31
Chief Operating Officer 39 2023-12-31
Director TitleAgeSince
Director/Board Member 60 2022-12-31
Chairman 66 2022-12-31
Director/Board Member 72 2022-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.97%+4.44% - - 180M
+0.35%-4.87%+49.87%+157.34% 1,031B
-2.69%-6.22%+59.19%+54.51% 595B
+0.44%-3.41%+30.97%+79.48% 431B
+0.98%-1.40%+29.49%+21.76% 326B
-0.34%-3.10%+27.00%+43.60% 277B
+1.63%-11.76%+19.72%+21.72% 263B
+3.39%+2.29%-23.68%-37.83% 224B
+0.86%-2.63%+22.50%+57.55% 193B
+1.28%-3.03%+20.76%+70.62% 164B
Average +0.19%-3.79%+26.20%+52.08% 389.37B
Weighted average by Cap. +0.21%-4.31%+35.59%+76.50%

Financials

2024 2025
Net sales 2.6M 270K 236K 218K 200K 379K 25.98M 386K 1.02M 12.7M 1.01M 992K 43.77M 2.5M 260K 227K 209K 192K 365K 24.98M 371K 981K 12.21M 975K 954K 42.09M
Net income -228M -23.68M -20.7M -19.1M -17.56M -33.26M -2.28B -33.83M -89.46M -1.11B -88.93M -86.98M -3.84B -757M -78.61M -68.73M -63.4M -58.28M -110M -7.56B -112M -297M -3.7B -295M -289M -12.74B
Net Debt -864M -89.76M -78.48M -72.4M -66.55M -126M -8.64B -128M -339M -4.22B -337M -330M -14.55B -538M -55.89M -48.86M -45.07M -41.43M -78.51M -5.38B -79.85M -211M -2.63B -210M -205M -9.06B
Logo InDex Pharmaceuticals Holding AB (publ)
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
Employees
-